BR9611647B1 - análogos citotóxicos colimados da antraciclina e composição contendo os mesmos. - Google Patents

análogos citotóxicos colimados da antraciclina e composição contendo os mesmos. Download PDF

Info

Publication number
BR9611647B1
BR9611647B1 BRPI9611647-1A BR9611647A BR9611647B1 BR 9611647 B1 BR9611647 B1 BR 9611647B1 BR 9611647 A BR9611647 A BR 9611647A BR 9611647 B1 BR9611647 B1 BR 9611647B1
Authority
BR
Brazil
Prior art keywords
group
dox
cytotoxic
formula
doxorubicin
Prior art date
Application number
BRPI9611647-1A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9611647A (pt
Inventor
Andrew V Schally
Attila A Nagy
Ren Zhi Cai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24247176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9611647(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BR9611647A publication Critical patent/BR9611647A/pt
Publication of BR9611647B1 publication Critical patent/BR9611647B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI9611647-1A 1995-11-27 1996-11-14 análogos citotóxicos colimados da antraciclina e composição contendo os mesmos. BR9611647B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US562652 1995-11-27
US08/562,652 US5843903A (en) 1995-11-27 1995-11-27 Targeted cytotoxic anthracycline analogs
PCT/EP1996/005029 WO1997019954A1 (en) 1995-11-27 1996-11-14 Targeted cytotoxic anthracycline analogs

Publications (2)

Publication Number Publication Date
BR9611647A BR9611647A (pt) 1999-02-23
BR9611647B1 true BR9611647B1 (pt) 2010-03-09

Family

ID=24247176

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9611647-1A BR9611647B1 (pt) 1995-11-27 1996-11-14 análogos citotóxicos colimados da antraciclina e composição contendo os mesmos.

Country Status (27)

Country Link
US (2) US5843903A (https=)
EP (2) EP1384710B1 (https=)
JP (2) JP3987575B2 (https=)
KR (2) KR100445754B1 (https=)
CN (2) CN1137136C (https=)
AT (2) ATE251179T1 (https=)
AU (1) AU709539B2 (https=)
BR (1) BR9611647B1 (https=)
CA (2) CA2238574C (https=)
CZ (1) CZ297297B6 (https=)
DE (2) DE69637604D1 (https=)
DK (2) DK0863917T3 (https=)
EA (1) EA001372B1 (https=)
ES (2) ES2310222T3 (https=)
HK (1) HK1052920B (https=)
HU (1) HU229870B1 (https=)
IL (3) IL119691A (https=)
IS (2) IS2178B (https=)
MX (1) MX9804119A (https=)
NO (2) NO324035B1 (https=)
NZ (1) NZ322054A (https=)
PL (3) PL188786B1 (https=)
PT (2) PT1384710E (https=)
SK (2) SK284672B6 (https=)
UA (1) UA67722C2 (https=)
WO (1) WO1997019954A1 (https=)
ZA (1) ZA969709B (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
IL142869A0 (en) 1998-11-13 2002-03-10 Cyclacel Ltd Transport vectors
FR2786397B1 (fr) * 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
FR2786398B1 (fr) * 1998-11-30 2002-12-27 Synt Em Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
US6380161B1 (en) 1999-06-21 2002-04-30 Inkine Pharmaceutical Company, Inc. Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions
JP2003513756A (ja) * 1999-11-12 2003-04-15 アンジオテック ファーマシューティカルズ，インコーポレイテッド 放射性治療と細胞周期インヒビターとの組合せの組成物
ATE344801T1 (de) 1999-12-29 2006-11-15 Immunogen Inc Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
JP2004517034A (ja) * 2000-04-26 2004-06-10 バイオシンセマ インコーポレーテッド （神経）ペプチド結合ｒｇｄ（ａｒｇ−ｇｌｙ−ａｓｐ）
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
KR100420007B1 (ko) * 2001-04-25 2004-03-02 노영쇠 안트라사이클린 유도체 및 이를 포함하는 항암제
BR0212897A (pt) 2001-09-21 2004-08-24 Univ Tulane Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos
EP1531846A4 (en) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
EP1487493B1 (en) 2002-03-01 2010-01-20 The Administrators of The Tulane Educational Fund Conjugates of cytotoxic agents and biologically active peptides
US7544767B2 (en) 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
WO2003097083A1 (en) * 2002-05-21 2003-11-27 Daiichi Suntory Pharma Co.,Ltd. Medicinal compositions containing ghrelin
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
EP2075014B9 (en) 2002-05-24 2012-02-01 Angiotech International Ag Compositions and methods for coating medical implants
KR20050084599A (ko) 2002-09-26 2005-08-26 안지오테크 인터내셔날 아게 혈관주위 랩
EP2181704B1 (en) 2002-12-30 2015-05-06 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US20050043215A1 (en) 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
NZ564694A (en) * 2003-04-22 2009-11-27 Sod Conseils Rech Applic Peptide vectors
AU2007221964B2 (en) * 2003-04-22 2008-12-11 Ipsen Pharma S.A.S. Peptide vectors
US7097993B2 (en) 2003-06-25 2006-08-29 Wisconsin Alumni Research Foundation Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity
WO2005086951A2 (en) * 2004-03-10 2005-09-22 Threshold Pharmaceuticals, Inc. Hypoxia-activated anti-cancer agents
US20070060534A1 (en) * 2005-06-30 2007-03-15 Threshold Pharmaceuticals, Inc. Anthracycline analogs
JP5340155B2 (ja) * 2006-09-06 2013-11-13 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 細胞結合分子を有するジソラゾールのコンジュゲート及びそれらの誘導体、新規ジソラゾール誘導体、それらの製法ならびに使用
EP1900742A1 (en) 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
WO2008100591A2 (en) * 2007-02-14 2008-08-21 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
RU2377247C2 (ru) * 2007-12-27 2009-12-27 Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет Молекулярный конъюгат на основе синтетических аналогов люлиберина и его применение в качестве средства доставки днк в клетки гормон-чувствительных опухолей (варианты)
US8742076B2 (en) * 2008-02-01 2014-06-03 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
ES2655243T3 (es) * 2008-04-11 2018-02-19 Tianjin Hemay Oncology Pharmaceutical Co., Ltd Derivados antibióticos de antraciclina con alta actividad, métodos de preparación y usos de los mismos
WO2009124468A1 (zh) * 2008-04-11 2009-10-15 天津和美生物技术有限公司 具有高活性的四环蒽醌类抗生素的衍生物及其制备和应用
CN102159248B (zh) * 2008-07-15 2013-09-11 健泰科生物技术公司 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途
CN102325545A (zh) 2009-02-20 2012-01-18 益普生制药股份有限公司 具有神经肽y受体结合化合物的细胞毒性缀合物
CN102050856B (zh) * 2009-11-03 2014-04-30 天津和美生物技术有限公司 具有高活性的表阿霉素的衍生物及其制备和应用
ES2533710T3 (es) 2010-12-02 2015-04-14 Nerviano Medical Sciences S.R.L. Proceso para la preparación de derivados de morfolinil antraciclina
CN105198966B (zh) * 2014-06-26 2019-06-21 中国人民解放军军事医学科学院毒物药物研究所 GnRH类似物-细胞毒分子缀合物、其制备方法及用途
CA2953371C (en) * 2014-06-30 2021-08-24 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
EP3045540A1 (en) 2015-01-19 2016-07-20 Æterna Zentaris GmbH Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters
JP7057278B2 (ja) 2015-10-28 2022-04-19 ターベダ セラピューティクス インコーポレイテッド Ｓｓｔｒ標的化コンジュゲート及び粒子並びにその製剤
US10450340B2 (en) 2017-02-16 2019-10-22 Monopar Therapeutics Inc. 3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
WO2021068051A1 (en) * 2018-11-13 2021-04-15 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
CA3246188A1 (en) 2022-03-25 2023-09-28 The University Of British Columbia Radiolabeled compounds for in vivo imaging of the gastrin-releasing peptide (GRPR) receptor and treatment of GRPR-related disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725350A (en) * 1972-04-26 1973-04-03 Commercial Soluents Corp Polymeric substances comprising the reaction product of melamine, aldehyde and oxazolidines
US4299822A (en) * 1980-06-09 1981-11-10 Sidney Farber Cancer Institute, Inc. N-Trifluoroacetyladriamycin-14-O-hemiglutarate and -hemiadipate and therapeutic compositions containing same
US4464529A (en) * 1982-07-20 1984-08-07 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
IL106992A (en) * 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5217955A (en) * 1989-09-15 1993-06-08 Biomeasure, Inc. Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin
DK0434960T3 (da) * 1989-12-19 1996-10-14 Pharmacia Spa Chirale 1,5-diiod-2-methoxy- eller benzyloxymellemprodukter
US5304687A (en) * 1989-12-19 1994-04-19 Farmitalia Carlo Erba S.R.L. Morpholinyl derivatives of doxorubicin and process for their preparation
ATE124054T1 (de) * 1990-04-06 1995-07-15 Univ Tulane Somatostatinanaloge.
DK0450461T3 (da) * 1990-04-06 1995-10-23 Univ Tulane LHRH-analoger
JP3169425B2 (ja) * 1992-03-27 2001-05-28 三共株式会社 アジドペンタンサイクリトール
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates

Also Published As

Publication number Publication date
KR100445754B1 (ko) 2004-12-08
AU7572296A (en) 1997-06-19
HUP9903771A2 (hu) 2000-02-28
KR100467899B1 (ko) 2005-01-24
MX9804119A (es) 1998-09-30
EA199800492A1 (ru) 1998-12-24
CN1202903A (zh) 1998-12-23
JP3987575B2 (ja) 2007-10-10
DK1384710T3 (da) 2008-11-17
HK1052920B (zh) 2005-03-04
JP4778405B2 (ja) 2011-09-21
CA2238574C (en) 2004-10-19
EP0863917A1 (en) 1998-09-16
CN1166597C (zh) 2004-09-15
ES2310222T3 (es) 2009-01-01
HU229870B1 (en) 2014-10-28
IS4734A (is) 1998-05-05
IL134685A0 (en) 2001-04-30
PL191781B1 (pl) 2006-07-31
CZ297297B6 (cs) 2006-11-15
EP1384710B1 (en) 2008-07-16
EP0863917B1 (en) 2003-10-01
PL188786B1 (pl) 2005-04-29
PT1384710E (pt) 2008-10-08
NO20051111L (no) 2005-03-01
EP1384710A1 (en) 2004-01-28
IS2634B (is) 2010-06-15
WO1997019954A1 (en) 1997-06-05
CA2238574A1 (en) 1997-06-05
DK0863917T3 (da) 2004-01-19
JP2007045845A (ja) 2007-02-22
NO324035B1 (no) 2007-07-30
EA001372B1 (ru) 2001-02-26
IS2178B (is) 2006-12-15
ATE251179T1 (de) 2003-10-15
DE69630233D1 (de) 2003-11-06
JP2000502055A (ja) 2000-02-22
US5843903A (en) 1998-12-01
KR20040037176A (ko) 2004-05-04
PL326865A1 (en) 1998-10-26
NO982252L (no) 1998-05-15
CN1137136C (zh) 2004-02-04
SK62898A3 (en) 1999-06-11
NZ322054A (en) 1999-04-29
HUP9903771A3 (en) 2000-07-28
ES2205067T3 (es) 2004-05-01
IL119691A (en) 2002-02-10
BR9611647A (pt) 1999-02-23
CA2471775C (en) 2008-01-29
SK284392B6 (sk) 2005-03-04
IL134685A (en) 2002-12-01
US6184374B1 (en) 2001-02-06
NO982252D0 (no) 1998-05-15
ATE401305T1 (de) 2008-08-15
HK1052920A1 (en) 2003-10-03
ZA969709B (en) 1997-08-25
AU709539B2 (en) 1999-09-02
IL119691A0 (en) 1997-02-18
CA2471775A1 (en) 1997-06-05
DE69637604D1 (de) 2008-08-28
UA67722C2 (en) 2004-07-15
PL187230B1 (pl) 2004-06-30
IS8567A (is) 2006-11-09
PT863917E (pt) 2004-02-27
CN1405127A (zh) 2003-03-26
HK1017363A1 (en) 1999-11-19
CZ135798A3 (cs) 1998-10-14
SK284672B6 (sk) 2005-08-04
KR19990071672A (ko) 1999-09-27
DE69630233T2 (de) 2004-08-05

Similar Documents

Publication Publication Date Title
BR9611647B1 (pt) análogos citotóxicos colimados da antraciclina e composição contendo os mesmos.
Schlage et al. Anthracycline-GnRH derivative bioconjugates with different linkages: synthesis, in vitro drug release and cytostatic effect
JPH04224600A (ja) 細胞毒性成分を有する黄体形成ホルモン放出ホルモン類似体
AU748507B2 (en) Novel synthetic reaction and targeted cytotoxic anthracycline analogs obtained thereby
US8076453B2 (en) Kinin B1 receptor peptide agonists and uses thereof
UA76474C2 (en) Method for conversion of nitrogen of primary aminogroup - or --hydroxy of primary amine into nitrogen of monounsaturated compound
Miklán et al. Cell-penetrating and targeting peptide conjugates of antitumor drugs: Synthesis, chemical and in vitro biological characterization
HK1017363B (en) Targeted cytotoxic anthracycline analogs

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: ZENTARIS AG (DE)

B25A Requested transfer of rights approved

Free format text: ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/03/2010, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061204/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132250-71.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: ACINO PHARMA AG, ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, AGOURON PHARMACEUTICALA, ALCON LABORATORIES , ALZA CORPORATION.

B21B Extinction acc. art. 78, item ii - on waiver by the patentee, without prejudice to the rights of third parties

Free format text: SOLICITADA ATRAVES DA PETICAO 860130005827, DE 29/10/2013

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.61574/13 SECAO JUDICIARIA DO RIO DE JANEIRO - 13A VARA FEDERAL PROCESSO NO. 2013.51.01.132250-7 AUTOR: INPI-INSTITUTO NACIONAL DE PROPRIEDADE INDUSTRIAL REU(S): AGOURON PHARMACEUTICALS,INC, ACINO PHARMA AG, ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, ALZA CORPORATION,ALCON LABORATORIES,INC . DECISAO: ISTO POSTO, HOMOLOGO OS ACORDOS FIRMADOS, JULGANDO EXTINTO O PROCESSO COM RESOLUCAO DE MERITO, FORTE NO ART.269,III DO CODIGO DE PROCESSO CIVIL.

B15K Others concerning applications: alteration of classification

Ipc: C07K 7/23 (2006.01), A61K 47/62 (2017.0